CALCA and migraine disorder: The high rates of constipation disclosed by real world evaluation of the efficacy and safety of antibodies targeting the CGRP receptor or CGRP itself emphasize the need to closely monitor their intestinal adverse effect profile and in this way safeguard the success in migraine treatment.